PI-103

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H16N4O3
Molecular Weight	348.3553
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=CC(=C1)C2=NC(N3CCOCC3)=C4OC5=NC=CC=C5C4=N2

InChI

InChIKey=TUVCWJQQGGETHL-UHFFFAOYSA-N

InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2

HIDE SMILES / InChI

Molecular Formula	C19H16N4O3
Molecular Weight	348.3553
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 9 Target ID: P42336 Gene ID: 5290.0 Gene Symbol: PIK3CA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19584227	Inhibitor 8504	0.002 µM [IC50]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 4 Target ID: P42338 Gene ID: 5291.0 Gene Symbol: PIK3CB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19584227	Inhibitor 8504	0.003 µM [IC50]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform 9 Target ID: O00329 Gene ID: 5293.0 Gene Symbol: PIK3CD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19584227	Inhibitor 8504	0.003 µM [IC50]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 6 Target ID: P48736 Gene ID: 5294.0 Gene Symbol: PIK3CG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19584227	Inhibitor 8504	0.015 µM [IC50]
Serine/threonine-protein kinase mTOR 35 Target ID: P42345 Gene ID: 2475.0 Gene Symbol: MTOR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19584227	Inhibitor 8504	0.03 µM [IC50]
DNA-dependent protein kinase catalytic subunit 4 Target ID: P78527\|\|\|Q9UME3 Gene ID: 5591.0 Gene Symbol: PRKDC Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19584227	Inhibitor 8504	0.023 µM [IC50]
PI3-kinase p110-alpha subunit 41 Target ID: CHEMBL4005 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27224913\| https://www.ncbi.nlm.nih.gov/pubmed/27658642	Inhibitor 8504
Serine/threonine-protein kinase mTOR 35 Target ID: CHEMBL2842 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27224913	Inhibitor 8504

PubMed

Title	Date	PubMed
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.	2013-04-15	23398362
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.	2012	23300809
GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.	2011-12	21994956
Comprehensive analysis of kinase inhibitor selectivity.	2011-10-30	22037378
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.	2011-10-30	22037377
5-Methoxyflavanone induces cell cycle arrest at the G2/M phase, apoptosis and autophagy in HCT116 human colon cancer cells.	2011-08-01	21616090
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.	2011-01-27	20856197
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.	2010-12	21187475
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.	2010-11-24	21095574
Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption.	2010-10	20880397
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.	2010-04-01	19810100
Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.	2010-03-26	20361045
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.	2009-07	19584227
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.	2009-02-01	19176369
High-throughput screening compatible cell-based assay for interrogating activated notch signaling.	2009-02	19382889
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.	2007-09-01	17601739
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.	2007-05-01	17339109
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.	2006-05-19	16647110
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.	2006-05	16697955

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:57:30 GMT 2025` Edited by `admin` on `Mon Mar 31 22:57:30 GMT 2025`
Record UNII	YQX02F616F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIK-103

Preferred Name

English

PI-103

Common Name

English

PHENOL, 3-(4-(4-MORPHOLINYL)PYRIDO(3',2':4,5)FURO(3,2-D)PYRIMIDIN-2-YL)-

Systematic Name

English

Code System Code Type Description

CAS

371935-74-9